Search for:
Search for:
Healthcare Professionals
Publications
News
EspaƱol
Contact
Magazine
Radio
Get Educated
What is MS?
A chronic neurological disorder that affects the central nervous system, comprised of the brain...
More Details
Educational Materials
Common Questions
Lending Library
Symptoms
Treatment Options
Additional Resources
Research
MS Awareness Month
Donate
Get Help
Health & Wellness Program
Get educational materials and referrals, as well as the opportunity to participate in various...
Learn More
Grants & Programs
Awareness Campaigns
Support Groups
Events
Lending Library
Additional Resources
Get Involved
MS Awareness Month
An annual, nationwide campaign with goals to promote an understanding of MS, and to assist those...
Learn More
Advocacy
Buy from Partners
Volunteer
Businesses
MS Research Trials
Outreach
Awareness Campaigns
Host an Event
Events
Test Flyout
lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem ipsum dolor sit lorem...
Learn More
Events Calendar
Health & Wellness
Fundraisers
Support
Web & Teleconferences
MS Education
Host an Event
About Us
Programs & Grants
More Details
Overview
Press Room
Leadership
Financial Statements
Our Mission
Careers at MS Focus
Affiliations
News & Features
MS Focus At Sea
MS Focus At Sea offers educational programs, opportunities to meet old and new friends, and adventures for every...
/Events/MSF-Events/MSFocus-Cruise-For-A-Cause
Computer Program
The MS Focus Computer Program provides laptop or desktop computers for individuals with MS on...
/Get-Help/MSF-Programs-Grants/Computer-Program
Shop
Privacy
Terms of Use
Site Map
FDA approves Gilenya for pediatric relapsing MS
May 14, 2018
The U.S. Food and Drug Administration has approved Gilenya (fingolimod) for the treatment of children and adolescents from 10 to less than 18 years of age with relapsing forms of multiple sclerosis, making it the first disease-modifying therapy approved for these patients. This expands the age range for Gilenya, which was previously approved for patients aged 18 years and older with RMS.
The approval of Gilenya for younger patients was supported by PARADIGMS, a double-blind, randomized, multicenter Phase III safety and efficacy study of fingolimod versus interferon beta-1a, designed specifically for children and adolescents with RMS. The primary endpoint demonstrated that fingolimod reduced the rate of relapses (annualized relapse rate) by approximately 82 percent during a period of up to two years compared to interferon beta-1a intramuscular injections in children and adolescents (ages 10 and older) with relapsing MS. The safety profile of Gilenya in this study was overall consistent with that seen in previous clinical trials in adults. In this study, while more adverse events were reported in the interferon beta-1a group, severe adverse events were reported at a higher frequency in fingolimod-treated patients.
While MS is mostly diagnosed in adults, children and adolescents with the chronic disease often experience more frequent relapses and brain lesions than adults with MS.
MS Focus Lending Library
Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more